features: Policy

FDA approve tucatinib for advanced unresectable or metastatic HER2-positive breast cancer

Seattle Genetics have announced the U.S. Food and Drug Administration (FDA) have granted approval for tucatinib in combination with trastuzumab…

NICE response to COVID-19 infection – delivery of systemic anticancer treatments

In light of the ongoing COVID-19 pandemic, the National Institute for Health and Care Excellence (NICE) have put together a…

European cancer patients call for more access to innovation in oncology

At the European Cancer Congress 2017 in Amsterdam, the European Cancer Patient Coalition launched a new white paper on the…